Dihydrobinetin

Dihydrobinetin

SCHEMBL432880

O=C1c2ccc(O)cc2OC(c2cc(O)c(O)c(O)c2)C1O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYNJ2 O15056 3/20 0.64
SOST Q9BQB4 2/20 0.64
APP P05067 1/20 0.64
IDO1 P14902 1/20 0.58
NSD2 O96028 1/20 0.58
TDO2 P48775 1/20 0.58
ESR1 P03372 1/20 0.56
ESR2 Q92731 1/20 0.56
RECQL P46063 3/20 0.51
KDM4E B2RXH2 2/20 0.51
MAPT P10636 2/20 0.51
ALOX15 P16050 2/20 0.51
HSD17B10 Q99714 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
POLB P06746 1/20 0.51
GAA P10253 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
ALOX12 P18054 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dihydrobinetin SCHEMBL18177341 1.00 SYNJ2 (0.64) SYNJ2SOSTAPPIDO1NSD2
Dihydrorobinetin SCHEMBL432879 1.00 SYNJ2 (0.64) SYNJ2SOSTAPPIDO1NSD2
Dihydrorobinetin SCHEMBL30799354 1.00 SYNJ2 (0.64) SYNJ2SOSTAPPIDO1NSD2
Fustin SCHEMBL13640269 0.87 IDO1 (0.77) SYNJ2SOSTAPPIDO1NSD2
Fustin SCHEMBL30443589 0.87 IDO1 (0.77) SYNJ2SOSTAPPIDO1NSD2
Fustin SCHEMBL13583362 0.87 IDO1 (0.77) SYNJ2SOSTAPPIDO1NSD2
Fustin SCHEMBL29929489 0.87 IDO1 (0.77) SYNJ2SOSTAPPIDO1NSD2
Fustin SCHEMBL555237 0.87 IDO1 (0.77) SYNJ2SOSTAPPIDO1NSD2
Garbanzol SCHEMBL9663852 0.87 ESR1 (0.73) SYNJ2SOSTAPPIDO1NSD2
Garbanzol SCHEMBL29370332 0.87 ESR1 (0.73) SYNJ2SOSTAPPIDO1NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4580594-A1 ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS AnalytiCon Discovery - Zweigniederlassung der BRAIN Biotech AG (DE) 2025-07-09 EP claimed
WO-2024046834-A1 ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS ANALYTICON DISCOVERY GMBH (DE) 2024-03-07 WO claimed
EP-4331564-A1 ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS Analyticon Discovery GmbH (DE) 2024-03-06 EP claimed
US-20230148620-A1 STABILIZED OIL AND METHODS OF MAKING THE SAME CARGILL, INCORPORATED (US) 2023-05-18 US claimed
US-9828407-B2 Water soluble and activable phenolic derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives LIBRAGEN (FR) 2017-11-28 US claimed
US-20170295812-A1 STABILIZED OIL AND METHODS OF MAKING THE SAME CARGILL, INCORPORATED 2017-10-19 US claimed
EP-3200596-A1 STABILIZED OIL AND METHODS OF MAKING THE SAME Cargill, Incorporated (US) 2017-08-09 EP claimed
WO-2016053971-A1 STABILIZED OIL AND METHODS OF MAKING THE SAME CARGILL, INCORPORATED (US) 2016-04-07 WO claimed
US-20140088030-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES LIBRAGEN (FR) 2014-03-27 US claimed
EP-2027279-B1 Phenolic compounds with cosmetic and therapeutic applications LIBRAGEN (FR) 2012-04-18 EP claimed
EP-2173319-A2 COSMETIC COMPOSITION WITH ANTI-RADICAL PROPERTIES AND CORRESPONDING APPLICATION METHOD Yves Saint-Laurent Parfums (FR) 2010-04-14 EP claimed
CN-101611148-A Water-soluble phenolic derivatives for cosmetic and therapeutic applications on the skin LIBRAGEN (FR) 2009-12-23 CN claimed
WO-2009024671-A2 COSMETIC COMPOSITION WITH ANTI-RADICAL PROPERTIES AND CORRESPONDING APPLICATION METHOD YVES SAINT LAURENT PARFUMS (FR) 2009-02-26 WO claimed
EP-2027279-A2 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES Libragen (FR) 2009-02-25 EP claimed
WO-2007144368-A2 WATER SOLUBLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS LIBRAGEN (FR) 2007-12-21 WO claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
EP-0945126-A2 Cosmetic or dermatologic composition containing carnitine and/or an acylcarnitine and at least an antioxidant Beiersdorf Aktiengesellschaft (DE) 1999-09-29 EP claimed
US-5952391-A STABILIZING COSMETIC OR DERMATOLOGILICAL FORMULATIONS BEIERSDORF AG (DE) 1999-09-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088030-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES UGGT1, TYR, G6PD SYNJ2 2883/4885SOST 388/4885APP 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.